FDA Clears Siemens' CT Iterative Reconstruction Protocol
Siemens’ computed tomography (CT) iterative reconstruction protocol has been cleared by the FDA, the company announced Wednesday.
Siemens’ computed tomography (CT) iterative reconstruction protocol has been cleared by the FDA for domestic sale, the company announced Wednesday.
The Sinogram Affirmed Iterative Reconstruction (SAFIRE) algorithm for image reconstruction allows for a reduction of radiation dose in CT exams, the company said. Use of projection of faw data during the process enables a reduction of subtle image artifacts and thus an improvement in image quality.
SAFIRE helps reduce dose by up to 60 percent, compared to previous filtered back projection techniques, the company said.
SAFIRE’s reconstruction speed of 20 images per second enables reconstruction of a typical high-resolution thorax exam of 30 cm in 15 seconds, according to Siemens.
“Independent scientific validation of our products has always been a cornerstone of our development process. We are extremely excited that the FDA now recognizes these efforts and, to our knowledge, for the first time has allowed a quantitative dose reduction claim for an iterative reconstruction technique in the industry,: Stefan Ulzheimer, PhD, director of global scientific marketing, Siemens Healthcare Computed Tomography, said in a statement.
SAFIRE was unveiled at last year’s RSNA as a work-in-progress. It is available for Siemens SOMATOM Definition Flash and SOMATOM Definition AS CT systems and will be available on the Definition DS in mid-2012.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
